Clinical trials: Rituximab
Primary Central Nervous System Lymphoma
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients.
- Trial name
- NCT06541665
- Testing
- ONO-4059, Rituximab, Methotrexate
- Where
- 44 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers.
- Conditions
- Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
- Trial name
- NCT07226843
- Testing
- LY4584180, Rituximab
- Where
- 46 sites in United States, France and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Membranous Nephropathy
Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy
High-grade proteinuria is one of the key determinants of adverse renal prognosis in patients with primary membranous nephropathy (PMN).The main purpose of this study is to determine whether Rituximab combined with Cyclosporine is…
- Trial name
- NCT07861204
- Testing
- Rituximab combined with cyclosporine, rituximab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University First Hospital
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer.
- Conditions
- Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
- Trial name
- SYMPHONY-1 (NCT04224493)
- Testing
- Tazemetostat, Lenalidomide, Rituximab
- Where
- 204 sites in United States, Australia and 15 more
- Volunteers
- 599 people
- Sponsor
- Epizyme, Inc.
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
This phase I trial studies the side effects and best dose of avelumab, utomilumab, rituximab, ibrutinib, and combination chemotherapy in treating patients with diffuse large B-cell lymphoma or mantle cell lymphoma that has come…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma
- Trial name
- NCT03440567
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Indolent B-Cell Non-Hodgkin Lymphoma
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory…
- Trial name
- NCT03571568
- Testing
- BI-1206, Rituximab, Acalabrutinib
- Where
- 27 sites in United States, Brazil and 4 more
- Volunteers
- 140 people
- Sponsor
- BioInvent International AB
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing…
- Conditions
- Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT03719131
- Testing
- Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emory University
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy with or without glofitamab for the treatment of patients with untreated large B-cell lymphoma that grows and spreads…
- Conditions
- Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT04231877
- Testing
- Polatuzumab Vedotin, Rituximab, Prednisone
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Washington
Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or…
- Trial name
- NCT04442022
- Testing
- Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy)
- Where
- 38 sites in United States, China and 4 more
- Volunteers
- 501 people
- Sponsor
- Karyopharm Therapeutics Inc
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
This phase I trial studies the side effects and best dose of venetoclax when given together with lenalidomide and rituximab hyaluronidase in treating patients with follicular lymphoma and marginal zone lymphoma that has come back…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma
- Trial name
- NCT04447716
- Testing
- Venetoclax, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Mantle Cell Lymphoma
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in…
- Trial name
- NCT05976763
- Testing
- Zanubrutinib, Rituximab, Patient Observation
- Where
- 238 sites in United States
- Volunteers
- 421 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Mantle Cell Lymphoma (MCL)
A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
This is a multicenter, open-label, phase II study evaluating TT-01488 in combination with different anti-CD20 monoclonal antibody-containing regimens for the treatment of treatment-naïve mantle cell lymphoma (MCL).
- Trial name
- NCT07855016
- Testing
- TT-01488 Tablets, Rituximab, Immunomodulatory Agent
- Where
- 2 sites in China
- Volunteers
- 188 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
This pilot clinical trial studies gene therapy following combination chemotherapy in treating patients with acquired immune deficiency syndrome (AIDS)-related non-Hodgkin lymphoma.
- Conditions
- AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma
- Trial name
- NCT02337985
- Testing
- Prednisone, Rituximab, Etoposide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Primary Mediastinal Large B-Cell Lymphoma
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL).
- Trial name
- NCT04759586
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 233 sites in United States, Australia and 2 more
- Volunteers
- 244 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
A Phase II, open-label, two-arm, multicenter study evaluating the combination of epcoritamab with R-CHOP chemotherapy in patients with newly diagnosed, aggressive B-cell non-Hodgkin lymphoma.
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)
- Trial name
- NCT07588698
- Testing
- Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Carrie Ho, MD
Primary Central Nervous System Lymphoma
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
BACKGROUND: Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma. The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL.
- Trial name
- NCT02203526
- Testing
- Isavuconazole, TEDDI, Rituximab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem…
- Trial name
- MANGROVE (NCT04002297)
- Testing
- zanubrutinib, bendamustine, rituximab
- Where
- 176 sites in United States, Australia and 20 more
- Volunteers
- 510 people
- Sponsor
- BeOne Medicines
Lymphoma
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone…
- Trial name
- NCT04980222
- Testing
- Glofitamab, Tocilizumab, Doxorubicin
- Where
- 20 sites in United States, Denmark and 4 more
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma…
- Trial name
- NCT07015242
- Testing
- Rituximab, Methotrexate, Procarbazine
- Where
- 40 sites in United States, France and 1 more
- Volunteers
- 65 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
- Trial name
- NCT07231952
- Testing
- Pirtobrutinib, Venetoclax, Rituximab
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center